This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weiss, R. B. Articles by Hudis, C. A. Search for Related Content PubMed PubMed Citation Articles by Weiss, R. B. Articles by Hudis, C. A. Social Bookmarking                            What's this?

An On-Site Audit of the South African Trial of High-Dose Chemotherapy for Metastatic Breast Cancer and Associated Publications

From the Georgetown University Medical Center, Washington, DC; Independent Consultant, Johannesburg, South Africa; and Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to Raymond B. Weiss, MD, 15304 Narcissus Way, Rockville, MD 20853-1744; email: rayweissmd{at}aol.com

PURPOSE: The randomized study reported by Bezwoda et al of high-dose chemotherapy (HDC) for treatment of metastatic breast cancer was audited on site to verify the study results. Additional published studies were reviewed to determine whether they had been subject to the required institutional oversight.

PATIENTS AND METHODS: Ninety patients were reported to have been randomized and treated on this trial. A log of the names, hospital numbers, entry dates, and regimen received had been provided by the principal investigator. A search of more than 15,000 sets of medical records available from two Johannesburg hospitals was performed to locate records for as many of these 90 patients as possible. Standard auditing techniques were used. Additional clinical trials published by Bezwoda were compared against the minutes of the University of the Witwatersrand Committee for Research on Human Subjects to verify review and approval.

RESULTS: Records for only 61 of the 90 patients could be found. Of these 61, only 27 had sufficient records to verify eligibility for the trial by the published criteria. Of these 27, 18 did not meet one or more eligibility criteria. Only 25 patients appeared to have received their assigned therapy temporally associated with their enrollment date, and all but three of these 25 received HDC. The treatment details of individual patients were at great variance from the published data. Nine other trials reported by Bezwoda were not reviewed or approved by the appropriate institutional committee despite statements to the contrary in the publications.

CONCLUSION: The multiple publications of this study do not report verifiable data, and nine other publications coauthored by the principal investigator contain at least one major untrue statement.

R.B.W. and G.G.G. are independent consultants and provide research auditing services for various entities.

Published online before print at http://www.asco.org/jco/ascoindex.htm.

An electronic version of this article, with brief clinical details of selected patients in an Appendix, is available at the following Internet site: http://www.jco.org.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. P. Ioannidis and T. A Trikalinos An exploratory test for an excess of significant findings Clinical Trials, June 1, 2007; 4(3): 245 - 253. [Abstract] [PDF]

				P. Schmid, W. Schippinger, T. Nitsch, G. Huebner, V. Heilmann, W. Schultze, H. Hausmaninger, M. Wischnewsky, and K. Possinger Up-Front Tandem High-Dose Chemotherapy Compared With Standard Chemotherapy With Doxorubicin and Paclitaxel in Metastatic Breast Cancer: Results of a Randomized Trial J. Clin. Oncol., January 20, 2005; 23(3): 432 - 440. [Abstract] [Full Text] [PDF]

				R. C. F. Leonard, M. Lind, C. Twelves, R. Coleman, S. van Belle, C. Wilson, J. Ledermann, I. Kennedy, P. Barrett-Lee, T. Perren, et al. Conventional Adjuvant Chemotherapy Versus Single-Cycle, Autograft-Supported, High-Dose, Late-Intensification Chemotherapy in High-Risk Breast Cancer Patients: A Randomized Trial J Natl Cancer Inst, July 21, 2004; 96(14): 1076 - 1083. [Abstract] [Full Text] [PDF]

				L. Gianni High-dose chemotherapy for breast cancer: any use for it? Ann. Onc., May 1, 2002; 13(5): 650 - 652. [Full Text] [PDF]

				J. R. Gralow and R. B. Livingston University of Washington High-Dose Cyclophosphamide, Mitoxantrone, and Etoposide Experience in Metastatic Breast Cancer: Unexpected Cardiac Toxicity J. Clin. Oncol., September 15, 2001; 19(18): 3903 - 3904. [Full Text] [PDF]

				R. P. Abratt, D. A. Vorobiof, L. Goedhals, B. Rappaport, P. Ruff, and C. F. Slabber Scientific Fraud and International Research J. Clin. Oncol., August 1, 2001; 19(15): 3592 - 3592. [Full Text]

				L. Norton High-Dose Chemotherapy for Breast Cancer: ""How Do You Know?"" J. Clin. Oncol., June 1, 2001; 19(11): 2769 - 2770. [Full Text] [PDF]